Johnson & Johnson is in talks to break up Actelion Ltd. in its proposed acquisition, Reuters reported Dec. 29, citing "people familiar with the matter."
The deal would reportedly involve the separation of the Swiss biotechnology company's commercialized portfolio from its research and development assets, which would be placed in a new publicly traded company.
Reuters reported that Johnson & Johnson could offer Actelion around $260 per share in the deal, compared to its previously rejected offer that valued Actelion at about $26 billion.
The ownership and management structure for the new company is still being hashed out in the discussions, according to the anonymous sources.
A deal could reportedly be finalized by late January 2017.
The companies recently re-entered negotiations after the previous talks for a deal fell apart. French drugmaker Sanofi is also in advanced talks to acquire Actelion.